Pieris Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Pieris Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Pieris Pharmaceuticals Inc Strategy Report
- Understand Pieris Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Pieris Pharmaceuticals Inc (Pieris) is a clinical-stage biotechnology company that carries out the discovery and development of anticalin-based drugs. The company’s pipeline product includes inhaled IL-4Rα antagonist Anticalin protein. It offers drug candidates such as PRS-440, PRS-342 and PRS-352, PRS-060/AZD1402, PRS-220, among others. Pieris also carries out AstraZenca programs and Genetech programs against respiratory diseases. The company offers therapeutics for the treatment of respiratory diseases, oncology and other diseases. It leverages Anticalin technology platform to develop and advance its pipeline candidates. Pieris collaborates with AstraZeneca Plc, Boston Pharmaceuticals, Servier SAS, Genentech and Seattle Genetics Inc to develop drug candidates. It operates in the US, Australia and Germany. Pieris is headquartered in Boston, Massachusetts, the US.
Headquarters
United States of America
Address
225 Franklin Street, 26th Floor, Boston, Massachusetts, 02110
Website
www.pieris.com
Telephone
1 857 2468998
No of Employees
127
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PIRS (NASD)
Revenue (2022)
$25.9M
65.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
26.2%
(2022 vs 2021)
Market Cap*
$1.2B
Net Profit Margin (2022)
XYZ
55.4%
(2022 vs 2021)
* As of and is in US$
Pieris Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Duocalin |
| Respiratory Disease Drugs: | Pieris |
| PRS-060/AZD1402 | Anticalin |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Pieris Pharmaceuticals Inc | Bristol-Myers Squibb Co | United Therapeutics Corp | Puma Biotechnology Inc | Arcus Biosciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Boston | Princeton | Silver Spring | Los Angeles | Hayward |
| State/Province | Massachusetts | New Jersey | Maryland | California | California |
| No. of Employees | 127 | 34,100 | 1,168 | 185 | 577 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| James Geraghty | Chairman | Executive Board | 2017 | 68 |
| Stephen S. Yoder | Chief Executive Officer; Director; President | Executive Board | 2014 | 47 |
| Thomas Bures | Senior Vice President; Chief Financial Officer | Senior Management | 2021 | 48 |
| Hitto Kaufmann | Chief Scientific Officer; Senior Vice President | Senior Management | 2019 | 51 |
| Florian Witte | Vice President | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer